<DOC>
	<DOCNO>NCT00688701</DOCNO>
	<brief_summary>The purpose study evaluate benefit risk lixisenatide ( AVE0010 ) , comparison placebo , use 2-step dose titration regimen monotherapy , period 12 week treatment . The primary objective ass effect lixisenatide , comparison placebo , glycemic control use 2-step dose titration regimen term glycosylated hemoglobin ( HbA1c ) reduction ( absolute change ) Week 12 . Secondary objective assess effect lixisenatide , comparison placebo , glycemic control term HbA1c reduction use one-step dose titration regimen period 12 week , body weight , fast plasma glucose ( FPG ) , 2-hour postprandial plasma glucose ( PPG ) standardize meal , assess safety tolerability , pharmacokinetics ( PK ) anti-lixisenatide antibody development .</brief_summary>
	<brief_title>GLP-1 Receptor Agonist Lixisenatide Patients With Type 2 Diabetes Glycemic Control Safety Evaluation Monotherapy</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled , 4-arm , unbalanced design , parallel group study two-step titration regimen one-step titration regimen . The study double-blind regard active placebo treatment ; however neither study drug volume titration regimen ( , two-step one-step ) blind .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 diabetes mellitus , diagnose least 2 month time screen visit , treat antidiabetic agent HbA1c le ( &lt; ) 7 percent ( % ) great ( &gt; ) 10 % At time screen age &lt; legal age majority Pregnant breastfeed woman woman childbearing potential without effective contraceptive method birth control Type 1 diabetes mellitus Type 2 diabetes treat antidiabetic agent within 3 month precede study Fasting plasma glucose screen &gt; 250 milligram per deciliter ( mg/dL ) ( &gt; 13.9 millimole per liter [ mmol/L ] ) Body mass index less equal ( &lt; = ) 20 kilogram per square meter ( kg/m^2 ) Weight change 5 kg previous 3 month History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery , inflammatory bowel disease History metabolic acidosis , include diabetic ketoacidosis within previous year Hemoglobinopathy hemolytic anemia , receipt blood plasma product within previous 3 month History myocardial infarction , stroke , heart failure require hospitalization within previous 6 month Known history drug alcohol abuse within previous 6 month Cardiovascular , hepatic , neurological , endocrine disease , active malignant tumor major systemic disease patient short life expectancy make implementation protocol interpretation study result difficult , history presence clinically significant diabetic retinopathy , history presence macular edema likely require laser treatment within study period Uncontrolled inadequately control hypertension rest supine systolic diastolic blood pressure &gt; 180 millimeter mercury ( mmHg ) &gt; 95 mmHg , respectively Laboratory finding time screening : aspartate aminotransferase , alanine aminotransferase alkaline phosphatase : &gt; 2 time upper limit normal ( ULN ) laboratory range ; amylase and/or lipase : &gt; 3 ULN ; total bilirubin : &gt; 1.5 ULN ( except case Gilbert 's syndrome ) ; hemoglobin &lt; 11 gram/deciliter ( g/dL ) and/or neutrophil &lt; 1,500 per cubic mm ( mm^3 ) and/or platelet &lt; 100,000/mm^3 ; positive test Hepatitis B surface antigen and/or hepatitis C antibody Any clinically significant abnormality identify physical examination , laboratory test , electrocardiogram vital sign time screen judgment investigator sub investigator precludes safe completion study hinders efficacy assessment Patients consider investigator subinvestigator inappropriate study reason Use systemic glucocorticoid ( exclude topical application inhale form ) within previous 3 month Participation previous study lixisenatide Use investigational drug within 3 month prior study Endstage renal disease define calculated serum creatinine clearance &lt; 15 milliliter/minute and/or patient dialysis Clinically relevant history gastrointestinal disease associate prolonged nausea vomiting , include , limited gastroparesis gastroesophageal reflux disease require medical treatment , within previous 6 month History allergic reaction glucagon like peptide1 ( GLP1 ) agonist past metacresol Additional exclusion criterion end runin phase : informed consent withdrawal ; lack compliance singleblind placebo runin phase : 2 injection miss ; patient adverse event precludes inclusion study , assess investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>hyperglycemia , GLP-1</keyword>
</DOC>